BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals (BCRX) has announced its participation in three upcoming investor conferences. The company will present at the 2024 Jefferies London Healthcare Conference on November 20 at 5:00 a.m. ET, the 7th Annual Evercore HealthCONx Conference in Coral Gables on December 4 at 2:35 p.m. ET, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 8:30 a.m. ET. Live audio webcasts and replays will be available through BioCryst's website investor section.
BioCryst Pharmaceuticals (BCRX) ha annunciato la sua partecipazione a tre prossime conferenze per investitori. L'azienda presenterà alla 2024 Jefferies London Healthcare Conference il 20 novembre alle 5:00 ora ET, alla 7ª Annual Evercore HealthCONx Conference a Coral Gables il 4 dicembre alle 14:35 ora ET, e alla Piper Sandler 36ª Annual Healthcare Conference a New York il 5 dicembre alle 8:30 ora ET. Saranno disponibili webcast audio dal vivo e riproduzioni nella sezione investitori del sito web di BioCryst.
BioCryst Pharmaceuticals (BCRX) ha anunciado su participación en tres próximas conferencias para inversores. La compañía presentará en la 2024 Jefferies London Healthcare Conference el 20 de noviembre a las 5:00 a.m. ET, en la 7ª Conferencia Anual Evercore HealthCONx en Coral Gables el 4 de diciembre a las 2:35 p.m. ET, y en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York el 5 de diciembre a las 8:30 a.m. ET. Se ofrecerán emisiones de audio en vivo y repeticiones a través de la sección de inversores en el sitio web de BioCryst.
BioCryst Pharmaceuticals (BCRX)는 다가오는 세 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 2024 Jefferies London Healthcare Conference에서 11월 20일 오전 5시(ET)에, 7회 연례 Evercore HealthCONx Conference에서 12월 4일 오후 2시 35분(ET)에, 그리고 Piper Sandler 제36회 연례 헬스케어 회의에서 12월 5일 오전 8시 30분(ET)에 발표할 예정입니다. BioCryst의 웹사이트 투자자 섹션을 통해 라이브 오디오 웹캐스트와 다시보기도 제공될 예정입니다.
BioCryst Pharmaceuticals (BCRX) a annoncé sa participation à trois prochaines conférences pour investisseurs. La société présentera à la 2024 Jefferies London Healthcare Conference le 20 novembre à 5h00 heure ET, à la 7ème Conférence Annuelle Evercore HealthCONx à Coral Gables le 4 décembre à 14h35 heure ET, et à la 36ème Conférence Annuelle Healthcare de Piper Sandler à New York le 5 décembre à 8h30 heure ET. Des webcasts audio en direct et des rediffusions seront disponibles dans la section investisseurs du site web de BioCryst.
BioCryst Pharmaceuticals (BCRX) hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am 2024 Jefferies London Healthcare Conference am 20. November um 5:00 Uhr ET, an der 7. jährlichen Evercore HealthCONx Conference in Coral Gables am 4. Dezember um 14:35 Uhr ET und an der Piper Sandler 36. jährlichen Healthcare Conference in New York am 5. Dezember um 8:30 Uhr ET präsentieren. Live-Audio-Webcasts und Wiederholungen werden im Investorensegment von BioCrysts Website verfügbar sein.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
- 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.
- 7th Annual Evercore HealthCONx Conference in Coral Gables on Wednesday, December 4, 2024, at 2:35 p.m. ET.
- Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
When is BioCryst (BCRX) presenting at the Jefferies London Healthcare Conference 2024?
Which investor conferences will BioCryst (BCRX) attend in December 2024?
How can investors access BioCryst's (BCRX) conference presentations?
